Brunner, Hermine I https://orcid.org/0000-0001-9478-2987
Abud-Mendoza, Carlos https://orcid.org/0000-0002-3749-5831
Viola, Diego O
Calvo Penades, Inmaculada
Levy, Deborah
Anton, Jordi
Calderon, Julia E
Chasnyk, Vyacheslav G
Ferrandiz, Manuel A
Keltsev, Vladimir
Paz Gastanaga, Maria E
Shishov, Michael
Boteanu, Alina Lucica
Henrickson, Michael
Bass, Damon
Clark, Kenneth
Hammer, Anne
Ji, Beulah N
Nino, Antonio
Roth, David A
Struemper, Herbert
Wang, Mei-Lun
Martini, Alberto
Lovell, Daniel https://orcid.org/0000-0003-1604-0130
Ruperto, Nicolino https://orcid.org/0000-0001-8407-7782
Clinical trials referenced in this document:
Documents that mention this clinical trial
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (Results)
https://doi.org/10.1136/annrheumdis-2020-217101
THU0503 PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE)
https://doi.org/10.1136/annrheumdis-2020-eular.4441
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.4884
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities
https://doi.org/10.1136/annrheumdis-2018-213198
SAT0505 PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME
https://doi.org/10.1136/annrheumdis-2020-eular.4460
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Documents that mention this clinical trial
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (Results)
https://doi.org/10.1136/annrheumdis-2020-217101
THU0503 PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE)
https://doi.org/10.1136/annrheumdis-2020-eular.4441
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.4884
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities
https://doi.org/10.1136/annrheumdis-2018-213198
SAT0505 PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME
https://doi.org/10.1136/annrheumdis-2020-eular.4460
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Documents that mention this clinical trial
POS0529 OBINUTUZUMAB BENEFITS PATIENTS WITH ACTIVE LUPUS NEPHRITIS IRRESPECTIVE OF BASELINE PROTEINURIA SEVERITY: A POST HOC ANALYSIS OF THE PHASE II NOBILITY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1543
Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort
https://doi.org/10.1136/lupus-2024-001264
PO:11:297 Kidney function preservation with belimumab in patients with lupus nephritis receiving MMF standard therapy in BLISS-LN: improved proteinuria, clinical outcomes and biomarkers for belimumab vs placebo
https://doi.org/10.1136/lupus-2026-el.350
POS0689 A 6-MONTH OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.1583
1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
https://doi.org/10.1136/lupus-2022-lupus21century.69
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
https://doi.org/10.1136/annrheumdis-2020-217101
PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.125
OP0164 BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.3881
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
https://doi.org/10.1136/lupus-2021-000598
PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis
https://doi.org/10.1136/lupus-2022-elm2022.129
MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT
https://doi.org/10.1136/lupus-2022-000746
506 Belimumab (BEL) improves renal outcomes in active Lupus Nephritis (LN): a phase 3 randomized, Placebo (PBO)-controlled trial
https://doi.org/10.1136/lupus-2021-lupus21century.24
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification
https://doi.org/10.1136/lupus-2022-elm2022.126
Dialogue: A blissful future for lupus nephritis: harnessing repeat kidney biopsies to identify meaningful biomarkers of disease
https://doi.org/10.1136/lupus-2015-000083
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis
https://doi.org/10.2215/cjn.02520322
Documents that mention this clinical trial
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (Results)
https://doi.org/10.1136/annrheumdis-2020-217101
THU0503 PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE)
https://doi.org/10.1136/annrheumdis-2020-eular.4441
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.4884
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities
https://doi.org/10.1136/annrheumdis-2018-213198
SAT0505 PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME
https://doi.org/10.1136/annrheumdis-2020-eular.4460
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Documents that mention this clinical trial
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2022-eular.1820
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
https://doi.org/10.1007/s40268-021-00363-2
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (Results)
https://doi.org/10.1136/annrheumdis-2020-217101
THU0503 PLUTO TRIAL: SENSITIVITY ANALYSES OF SRI4 RESPONSE WITH BELIMUMAB VS PLACEBO IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (CSLE)
https://doi.org/10.1136/annrheumdis-2020-eular.4441
P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies
https://doi.org/10.1136/lupus-2020-eurolupus.172
FRI0181 THE PLUTO STUDY: INTRAVENOUS BELIMUMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2019-eular.4884
Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities
https://doi.org/10.1136/annrheumdis-2018-213198
SAT0505 PLUTO TRIAL OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (cSLE): PATIENT RESPONSES OVER TIME
https://doi.org/10.1136/annrheumdis-2020-eular.4460
Belimumab in systemic lupus erythematosus
https://doi.org/10.1136/rmdopen-2014-000011
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
https://doi.org/10.1136/rmdopen-2021-001747
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports
https://doi.org/10.1136/ard-2022-222505
Funding for this research was provided by:
GlaxoSmithKline (GSK study BEL114055)
This article is maintained by: Elsevier
Article Title: Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2020-217101
Content Type: article
Copyright: Copyright © 2020 © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.